Preparation and in vivo biological investigations on a novel radioligand for bone scanning: Technetium-99m-labeled zoledronic acid derivative

Nuclear Medicine and Biology

Volumn 38, Issue 5, 2011, Pages 619-629

  Lin, Jianguo ^a   Qiu, Ling ^a   Cheng, Wen ^a   Luo, Shineng ^a   Ye, Wanzhong ^a  

^a JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

Author keywords

99mTc IPrDP; Biodistribution; Bone scanning; Diphosphonic acid; Pharmacokinetics

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE; MEDRONATE TECHNETIUM TC 99M; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 1 HYDROXY 3 (1H IMIDAZOL 1 YL)PROPANE 1,1 DIYLDIPHOSPHONIC ACID TC 99M; TECHNETIUM ZOLEDRONIC ACID TC 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE SCINTISCANNING; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; OSTEOLYSIS; PLASMA CLEARANCE; RABBIT; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BLOOD PROTEINS; BONE AND BONES; DIPHOSPHONATES; DRUG STABILITY; IMIDAZOLES; KINETICS; LIGANDS; MICE; ORGANOTECHNETIUM COMPOUNDS; QUALITY CONTROL; RABBITS; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79959629737     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.12.005     Document Type: Article

References (25)

1. Subramanian G., McAfee J.G., Blair R.J., Kallfelz F.A., Thomas F.D. Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975, 16:744-755.
2. Cole T.J., Balseiro J., Lippman H.R. Technetium-99m-methylene diphosphonate (MDP) uptake in a sympathetic effusion: an index of malignancy and a review of the literature. J Nucl Med 1991, 32:325-327.
3. Shalaby-Rana E., Majd M. 99mTc-MDP scintigraphic findings in children with leukemia: value of early and delayed whole-body imaging. J Nucl Med 2001, 42:878-883.
4. Sahin M., Yildiz M., Tunc S.E., Cerci S., Suslu H., Cure E., et al. The usefulness of Tc-99m-MDP bone scintigraphy in detection of articular involvement of Behçet's disease. Ann Nucl Med 2006, 20:649-653.
5. O'Connor A.R., Birchall J.D., O'Connor S.R., Bessell E. The value of 99mTc-MDP bone scintigraphy in staging primary lymphoma of bone. Nucl Med Commun 2007, 28:529-531.
6. Love C., Din A.S., Tomas M.B., Kalapparambath T.P., Palestro C.J. Radionuclide bone imaging: an illustrative review. Radiographics 2003, 23:341-358.
7. Ogawa K., Mukai T., Inoue Y., Ono M., Saji H. Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 2006, 47:2042-2047.
8. Smith M.R. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol-Semin Ori 2008, 26:420-425.
9. Zhu H., Huang L.L., Zhang Y.Q., Xu X.P., Sun Y.H., Shen Y.M. Design, synthesis, and evaluation of cyclofenil derivatives for potential SPECT imaging agents. J Biol Inorg Chem 2010, 15:591-599.
10. Wang H.Y., Luo S.N., Xie M.H., Liu X.Y., Feng Y.Y., Chen Z.M., et al. The new bone imaging agent: Preparation and biodistribution of 99Tcm-ZL. Nucl Tech (in Chinese) 2006, 29:438-441.
11. Niu G.S., Luo S.N., Yan X.H., Yang M., Ye W.Z., Wang H.Y., et al. The preparation and biodistribution of 99Tcm-EIDP. Nucl Tech (in Chinese) 2008, 31:698-701.
12. Chen C.Q., Luo S.N., Lin J.G., Yang M., Ye W.Z., Qiu L., et al. Preparation and biodistribution of 99Tcm-PIDP as bone imaging agent. Nucl Sci Tech 2009, 20:302-306.
13. Lin J.G., Luo S.N., Chen C.Q., Qiu L., Wang Y., Cheng W., et al. Preparation and preclinical pharmacological study on a novel bone imaging agent 99mTc-EMIDP. Appl Radiat Isotopes 2010, 68:1616-1622.
14. Widler L., Jaeggi K.A., Glatt M., Müller K., Bachmann R., Bisping M., et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002, 45:3721-3738.
15. Nayak T.K., Hathaway H.J., Ramesh C., Arterburn J.B., Dai D.H., Sklar L.A., et al. Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. J Nucl Med 2008, 49:978-986.
16. Koudelkova M., Jedinakova-Krizova V. Capillary electrophoretic and thin-layer chromatographic characterization of rhenium complexation with 1-hydroxyethylidenediphosphonic acid. J Chromatogr A 2003, 990:317-323.
17. Asikoglu M., Durak F.G. The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m. Appl Radiat Isotopes 2009, 67:1616-1621.
18. El-Mabhouha A., Mercer J.R. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases. Appl Radiat Isotopes 2005, 62:541-549.
19. Major P., Lortholary A., Hon J., Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558-567.
20. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005, 10:52-62.
21. Guo X.H., Luo S.N., Wang H.Y., Zhou L., Xie M.H., Ye W.Z., et al. Study on the preparation and biodistribution of 99mTc-HMIBP. Nucl Sci Tech 2006, 17:285-288.
22. Valko K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J Chromatogr A 2004, 1037:299-310.
23. El-Mabhouh A.A., Angelov C.A., Cavell R., Mercer J.R. A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer. Nucl Med Biol 2006, 33:715-722.
24. Liu R.S., Chou T.K., Chang C.H., Wu C.Y., Chang C.W., Chang T.J., et al. Biodistribution, pharmacokinetics and PET Imaging of [18F]FMISO, [18F]FDG and [18F]FAc in a sarcoma- and inflammation-bearing mouse model. Nucl Med Biol 2009, 36:305-312.
25. Vallner J.J. Binding of drugs by albumin and plasma protein. J Pharm Sci 1977, 66:447-465.